Noxopharm Past Earnings Performance
Past criteria checks 0/6
Noxopharm's earnings have been declining at an average annual rate of -9.5%, while the Biotechs industry saw earnings growing at 13.2% annually. Revenues have been declining at an average rate of 4.3% per year.
Key information
-9.5%
Earnings growth rate
14.2%
EPS growth rate
| Biotechs Industry Growth | 9.6% |
| Revenue growth rate | -4.3% |
| Return on equity | -65.1% |
| Net Margin | -149.1% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Noxopharm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 2 | -4 | 4 | 0 |
| 31 Mar 24 | 3 | -8 | 4 | 0 |
| 31 Dec 23 | 4 | -12 | 5 | 0 |
| 30 Sep 23 | 5 | -14 | 5 | 0 |
| 30 Jun 23 | 6 | -15 | 6 | 0 |
| 31 Mar 23 | 6 | -15 | 6 | 0 |
| 31 Dec 22 | 7 | -15 | 7 | 0 |
| 30 Sep 22 | 6 | -17 | 7 | 0 |
| 30 Jun 22 | 5 | -19 | 7 | 0 |
| 31 Mar 22 | 6 | -15 | 7 | 0 |
| 31 Dec 21 | 6 | -11 | 6 | 0 |
| 30 Sep 21 | 6 | -10 | 7 | 0 |
| 30 Jun 21 | 6 | -9 | 7 | 0 |
| 31 Mar 21 | 6 | -5 | 7 | 0 |
| 31 Dec 20 | 6 | 0 | 7 | 0 |
| 30 Sep 20 | 7 | 0 | 8 | 0 |
| 30 Jun 20 | 8 | 0 | 8 | 0 |
| 31 Mar 20 | 6 | -7 | 9 | 2 |
| 31 Dec 19 | 4 | -15 | 10 | 4 |
| 30 Sep 19 | 4 | -13 | 10 | 5 |
| 30 Jun 19 | 4 | -11 | 9 | 7 |
| 31 Mar 19 | 4 | -11 | 9 | 6 |
| 31 Dec 18 | 3 | -10 | 8 | 5 |
| 30 Sep 18 | 2 | -14 | 7 | 4 |
| 30 Jun 18 | 1 | -18 | 6 | 4 |
| 31 Mar 18 | 1 | -16 | 5 | 3 |
| 31 Dec 17 | 1 | -14 | 4 | 3 |
| 30 Sep 17 | 1 | -8 | 3 | 2 |
| 30 Jun 17 | 0 | -3 | 2 | 1 |
| 31 Mar 17 | 0 | -3 | 2 | 1 |
Quality Earnings: NOX is currently unprofitable.
Growing Profit Margin: NOX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NOX is unprofitable, and losses have increased over the past 5 years at a rate of 9.5% per year.
Accelerating Growth: Unable to compare NOX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NOX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: NOX has a negative Return on Equity (-65.11%), as it is currently unprofitable.